<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01882400</url>
  </required_header>
  <id_info>
    <org_study_id>01-12</org_study_id>
    <secondary_id>Unrestricted grant</secondary_id>
    <nct_id>NCT01882400</nct_id>
  </id_info>
  <brief_title>Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy</brief_title>
  <official_title>Évaluation Multidimensionnelle de la réponse au Traitement de l'ostéoporose spontanée et Induite Par Les corticostéroïdes à l'Aide d'un Bisphosphonate à Administration Orale Chez Des Malades Porteurs d'Une Dystrophie Musculaire sévère.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilles Boire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By supplying an adequate amount of calcium and vitamin D with the addition of weekly
      bisphosphonate, the investigators will be able to increase bone mass and decrease the
      incidence of fragility fractures in these children with muscular dystrophy.

      The investigators think this treatment will also decrease the intensity of pain frequently
      present in these patients and slow the progression of scoliosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with muscular dystrophy, as well as children with other chronic diseases (e.g.
      cystic fibrosis, chronic inflammatory arthritis) are at risk to develop fragility fractures
      both due to the disease itself and to drugs (mostly corticosteroids) used to treat the
      diseases.

      In addition, children with muscular dystrophy frequently complain of diffuse pain making
      daily care more difficult and almost always develop structural scoliosis.

      The objective of the present protocol is to offer these children a preventive treatment aimed
      at maintaining or increasing their bone mass. We also propose that maintaining bone mass will
      decrease fracture rates, as well as pain and the rate of progression of scoliosis.

      Rigorous care to ensure adequate intake of calcium and vitamin D, as well as addition of a
      weekly bisphosphonate, are the central aspect of the project. In addition, we will monitor to
      avoid possible side-effects such as hypercalciuria and kidney stones.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in bone density according to osteodensitometry</measure>
    <time_frame>Over 2 years of treatment</time_frame>
    <description>comparing successive bone densitometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in bone pain</measure>
    <time_frame>Over the first 2 years of treatment</time_frame>
    <description>comparing reports of bone pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retardation of scoliosis development</measure>
    <time_frame>Over the first 2 years of treatment</time_frame>
    <description>computing how many patients had to have scoliosis surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Side effects of treatment</measure>
    <time_frame>Over 2 years</time_frame>
    <description>Look for increases in kidney stones or hypercalciuria</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Muscular Dystrophy</condition>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Bisphosphonate treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Add a weekly bisphosphonate to adequate doses of calcium and vitamin D supplements</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bisphosphonate treatment</intervention_name>
    <description>Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment</description>
    <arm_group_label>Bisphosphonate treatment</arm_group_label>
    <other_name>Risedronate</other_name>
    <other_name>Alendronate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoporosis or osteopenia

          -  Severe muscular dystrophy or cystic fibrosis

          -  May use corticosteroids

        Exclusion Criteria:

          -  Inability to consent or to take drugs by mouth
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Boire, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHUS and Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2013</study_first_posted>
  <last_update_submitted>January 6, 2018</last_update_submitted>
  <last_update_submitted_qc>January 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Gilles Boire</investigator_full_name>
    <investigator_title>Doctor Gilles Boire</investigator_title>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Severe muscular dystrophy</keyword>
  <keyword>Cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

